3
Goa-based molecular diagnostics firm Molbio closed FY25 with Rs 1,020 crore in revenue and Rs 138.5 crore profit, marking a sharp recovery from its post-COVID slump. The Temasek-backed unicorn, which had shot into the limelight during the pandemic, saw its revenue peak at Rs 1,272 crore in FY21 before crashing to Rs 332 crore in FY23.
According to its draft red herring prospectus (DRHP) filed with SEBI, Molbio’s scale grew 22% from Rs 836 crore in FY24 while its profits surged 66% during FY25, underlining the company’s turnaround ahead of its…
